The funding round will support Leucine in refining its AI capabilities and making its AI Co-pilot a trusted partner to the production and quality managers
Leucine, a B2B SaaS start-up has secured a $7 million Series A funding round led by Ecolab Inc. and joined by Pravega Ventures, Axilor Ventures, Techstars, and angel investors. This funding will accelerate the company’s Compliance Cloud platform, armed with AI-driven tools, to transform pharmaceutical manufacturing, aligning with industry demands.
The company announced the beta launch of Leucine 10x, an AI framework designed to serve as a co-pilot in pharmaceutical manufacturing processes.
Vivek Gera, CEO and co-founder of Leucine said: “Paper-based manufacturing records are the industry's Achilles' heel, fueling not only regulatory nightmares but also ballooning production costs and inefficiencies. The legacy solutions are no better, with their extremely long implementation cycles and rigid, siloed applications that leave manufacturers in a lurch.”
“Vivek and Mustaq have been relentless in their mission to make pharma manufacturing safer. This latest funding round will enable Leucine to bring the power of LLMs and associated technologies to make significant advances in pharma manufacturing. We couldn’t be happier to support them in this quest” said Rohit Jain, co-founder and partner at Pravega Ventures.
The company claimed that its platform can be implemented in 8 weeks. This speed of implementation becomes possible because of the proprietary AI-enabled digital process builder based on Large Language Models (LLMs) that rapidly digitises paper SOPs into execution-ready digital formats.
"Our models are trained on a wealth of pharma data, which allows the platform to create custom workflows enriched with GxP compliance measures, enabling us to deliver unparalleled value at breakneck speed," added Vivek Gera. A batch execution procedure is the single most important document in pharma manufacturing. This rapid digitisation capability reduces the digitisation cycle of a batch record from 6-8 months to 3-5 days.”
Leucine is currently deployed at over 30 companies in over 300 pharma manufacturing facilities across 10 countries, including the US, India, Brazil, Mexico, UAE, and others. Over the last 12 months, the company has seen a 2X jump in the total number of manufacturing facilities using its product.